Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Duployez

Showing results (71-80 of 141) with videos related to

Pageof 15
Sort By:
Blood|April 26, 2018
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemiaRaphael Itzykson, Nicolas Duployez, Annette Fasan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2024
Influence of Nucleophosmin (<i>NPM1</i>) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup CollaborationClaudia Tregnago, Maddalena Benetton, Rhonda E Ries, et al.
Blood Cancer Journal|May 28, 2026
Ultra-high-sensitivity next-generation sequencing-based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohortAugustin Boudry, Laurène Fenwarth, Raphaël Itzykson, et al.
Blood|June 29, 2014
Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocationsJean-Baptiste Micol, Nicolas Duployez, Nicolas Boissel, et al.
British Journal of Haematology|February 28, 2020
Baseline dysmegakaryopoiesis in inherited thrombocytopenia/platelet disorder with predisposition to haematological malignanciesElise Fournier, Camille Debord, Valérie Soenen, et al.
Cancers|May 5, 2021
The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated IntensivelyMaël Heiblig, Nicolas Duployez, Alice Marceau, et al.
Hemasphere|November 15, 2019
Germline <i>RUNX1</i> Intragenic Deletion: Implications for Accurate Diagnosis of FPD/AMLNicolas Duployez, Jean-Edouard Martin, Sabine Khalife-Hachem, et al.
Nature Communications|May 19, 2017
ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemiaJean-Baptiste Micol, Alessandro Pastore, Daichi Inoue, et al.
Signal Transduction and Targeted Therapy|April 21, 2026
Surface CD81 supports leukemia stem cell function and reveals a therapeutic vulnerability in acute myeloid leukemiaFanny Gonzales, Pauline Peyrouze, Djohana Laurent, et al.
Blood Advances|October 9, 2021
Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AMLJuliette Lambert, Jerome Lambert, Xavier Thomas, et al.
Pageof 15

Showing results (71-80 of 141) with videos related to

Sort By:
Pageof 15
Blood|April 26, 2018
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemiaRaphael Itzykson, Nicolas Duployez, Annette Fasan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2024
Influence of Nucleophosmin (<i>NPM1</i>) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup CollaborationClaudia Tregnago, Maddalena Benetton, Rhonda E Ries, et al.
Blood Cancer Journal|May 28, 2026
Ultra-high-sensitivity next-generation sequencing-based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohortAugustin Boudry, Laurène Fenwarth, Raphaël Itzykson, et al.
Blood|June 29, 2014
Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocationsJean-Baptiste Micol, Nicolas Duployez, Nicolas Boissel, et al.
British Journal of Haematology|February 28, 2020
Baseline dysmegakaryopoiesis in inherited thrombocytopenia/platelet disorder with predisposition to haematological malignanciesElise Fournier, Camille Debord, Valérie Soenen, et al.
Cancers|May 5, 2021
The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated IntensivelyMaël Heiblig, Nicolas Duployez, Alice Marceau, et al.
Hemasphere|November 15, 2019
Germline <i>RUNX1</i> Intragenic Deletion: Implications for Accurate Diagnosis of FPD/AMLNicolas Duployez, Jean-Edouard Martin, Sabine Khalife-Hachem, et al.
Nature Communications|May 19, 2017
ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemiaJean-Baptiste Micol, Alessandro Pastore, Daichi Inoue, et al.
Signal Transduction and Targeted Therapy|April 21, 2026
Surface CD81 supports leukemia stem cell function and reveals a therapeutic vulnerability in acute myeloid leukemiaFanny Gonzales, Pauline Peyrouze, Djohana Laurent, et al.
Blood Advances|October 9, 2021
Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AMLJuliette Lambert, Jerome Lambert, Xavier Thomas, et al.
Pageof 15